Hyperacute rejection in ex vivo‐perfused porcine lungs transgenic for human complement regulatory proteins

Inhibition of complement activation via human membrane‐associated complement regulators is known to prevent hyperacute rejection in heart and kidney pig‐to‐primate transplantation. The protective effect of such strategies in pulmonary xenografts, however, seems to be insufficient. In an ex vivo perfusion, model lungs from donor pigs transgenic for human CD55 (n = 6) or human CD59 (n = 5) were perfused with fresh human blood and compared with nontransgenic organs (n = 6). In addition, a soluble complement component 1 esterase inhibitor (C1‐Inh) was applied in h‐CD55 transgenic lungs (n = 3). In the h‐CD55 transgenic group, survival was prolonged (P < 0.05), quality and maximal time of oxygenation significantly improved and pulmonary vascular resistance reduced compared with the control group. There was a decreased sequestration of platelets, less parenchymal injury and reduced deposition of C5b−9 in the h‐CD55 transgenic group. Additional soluble complement inhibition (C1‐Inh) did not prolong survival of h‐CD55 transgenic lungs. Survival and pulmonary function in lungs expressing h‐CD59 was not significantly different from parameters observed in nontransgenic lungs. In this ex vivo model of pig‐to‐primate lung transplantation, membrane‐based complement inhibition resulted in significantly improved pulmonary function. However, minor histopathological injuries observed in these transgenic xenografts suggested only partial protection from pulmonary dysfunction by complement inhibition alone.

[1]  P. Morel,et al.  Xenotransplantation: an update on recent progress and future perspectives , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  R. Pierson,et al.  Beyond antibody-mediated rejection: hyperacute lung rejection as a paradigm for dysregulated inflammation. , 2005, Current drug targets. Cardiovascular & haematological disorders.

[3]  R. Pierson,et al.  Hyperacute Lung Rejection in the Pig-to-Human Model 4: Evidence for Complement and Antibody Independent Mechanisms , 2005, Transplantation.

[4]  Hong Wang,et al.  Improved suppression of circulating complement does not block acute vascular rejection of pig‐to‐rhesus monkey cardiac transplants , 2004, Xenotransplantation.

[5]  J. Platt,et al.  Pulmonary xenotransplantation: Rapidly progressing into the unknown , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  R. Pierson,et al.  Effect of complement fragment 1 esterase inhibition on survival of human decay-accelerating factor pig lungs perfused with human blood. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  T. Mollnes,et al.  Perspectives on complement in xenotransplantation. , 2003, Molecular immunology.

[8]  R. Pierson,et al.  Hyperacute lung rejection in the pig-to-human model. III. platelet receptor inhibitors synergistically modulate complement activation and lung injury , 2003, Transplantation.

[9]  R. Pierson,et al.  Hyperacute lung rejection in the pig‐to‐human model. 2. Synergy between soluble and membrane complement inhibition , 2003, Xenotransplantation.

[10]  A. Boquest,et al.  Transgenic perspectives in xenotransplantation, 2001 , 2002, Xenotransplantation.

[11]  J. Platt,et al.  Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. , 2002, Transplantation.

[12]  G. Gonzalez-Stawinski,et al.  Non-anti-Gal alpha1-3Gal antibody mechanisms are sufficient to cause hyperacute lung dysfunction in pulmonary xenotransplantation. , 2002, Journal of the American College of Surgeons.

[13]  H. Schuurman,et al.  Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors , 2002, Transplantation.

[14]  W. Fecke,et al.  Protection of hDAF‐transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex , 2002, Xenotransplantation.

[15]  H. Hauser,et al.  CYTOMEGALOVIRUS EARLY PROMOTER INDUCED EXPRESSION OF hCD59 IN PORCINE ORGANS PROVIDES PROTECTION AGAINST HYPERACUTE REJECTION1 , 2001, Transplantation.

[16]  T. Ishizaka,et al.  Creation of long lasting luminescence in transparent aluminas , 2001 .

[17]  T. Mollnes,et al.  C1-inhibitor: an anti-inflammatory reagent with therapeutic potential , 2001, Expert opinion on pharmacotherapy.

[18]  R. Pierson,et al.  Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. , 2001, Journal of applied physiology.

[19]  Stefan Fischer,et al.  Low-potassium dextran preservation solution improves lung function after human lung transplantation. , 2000, The Journal of thoracic and cardiovascular surgery.

[20]  J. Platt,et al.  The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. , 2000, The Journal of thoracic and cardiovascular surgery.

[21]  A. Dalmasso,et al.  Transgenic swine lungs expressing human CD59 are protected from injury in a pig-to-human model of xenotransplantation. , 2000, The Journal of thoracic and cardiovascular surgery.

[22]  V. Videm,et al.  C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. , 1999, Immunopharmacology.

[23]  J. Platt,et al.  Human complement regulatory proteins protect swine lungs from xenogeneic injury. , 1999, The Annals of thoracic surgery.

[24]  M. Goddard,et al.  Orthotopic heart transplantation in a transgenic pig-to-primate model. , 1998, Transplantation.

[25]  J. Platt,et al.  Complement-mediated pulmonary xenograft injury: studies in swine-to-primate orthotopic single lung transplant models. , 1998, Transplantation.

[26]  M. O'connell,et al.  Characterization of pigs transgenic for human decay-accelerating factor. , 1997, Transplantation.

[27]  P. Dartevelle,et al.  Ex vivo lung model of pig-to-human hyperacute xenograft rejection. , 1997, The Journal of thoracic and cardiovascular surgery.

[28]  P. Ward.  Recruitment of inflammatory cells into lung: roles of cytokines, adhesion molecules, and complement. , 1997, The Journal of laboratory and clinical medicine.

[29]  R. Pierson,et al.  Hyperacute lung rejection in a pig-to-human transplant model: the role of anti-pig antibody and complement. , 1997, Transplantation.

[30]  J. Platt,et al.  Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model. , 1997, The Journal of thoracic and cardiovascular surgery.

[31]  J. Platt,et al.  Prolongation of cardiac xenograft survival by depletion of complement. , 1993, Transplantation.

[32]  P. Sims,et al.  The response of human platelets to activated components of the complement system. , 1991, Immunology today.

[33]  J. Platt,et al.  Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. , 1991, Transplantation.